ModifiedPremera BluecrossPolicy G2061

Fecal calprotectin testing for diagnosis and monitoring of inflammatory bowel disease

This policy governs coverage and clinical use of fecal calprotectin testing (CPT 83993) for individuals 18 years and older, including differential diagnosis between IBD and IBS and monitoring/assessment of IBD treatment response or relapse.

Policy Summary

PayerPremera Bluecross

PolicyFecal calprotectin testing for diagnosis and monitoring of inflammatory bowel disease

Policy CodePolicy G2061

Change TypeNew policy insertion

Effective DateFeb 6, 2026

Next Review Date

Key ActionDocument patient age (≥18), clinical indication, and link testing to management decisions when submitting claims for CPT 83993.

SourceLink

POLICY UPDATE CHANGES

For adults aged 18 or older, fecal calprotectin testing is reimbursable for differentiating non-inflammatory (e.g., irritable bowel syndrome) from inflammatory gastrointestinal disease (e.g., inflammatory bowel disease [IBD]) and for assessing response to therapy, relapse, or monitoring IBD.

18+age group this policy applies to

83993listed CPT code for test

50 µg/gcommonly cited cutoff

150 µg/ghigher cutoff referenced

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Fecal Calprotectin Testing

Reimbursable Indications

Covered when meeting the following age and indication conditions

Adult differential diagnosis: Patient is at least 18 years of age AND fecal calprotectin testing is ordered to differentiate non-inflammatory gastrointestinal disease (e.g., irritable bowel syndrome) from inflammatory gastrointestinal disease (e.g., inflammatory bowel disease).age >= 18

Reimbursable per policy indication 1

Monitoring/assessment in IBD: Patient is at least 18 years of age AND testing is ordered to assess response to therapy, detect relapse, or monitor disease activity in patients with known inflammatory bowel disease (IBD).age >= 18

Reimbursable per policy indication 2

Reimbursable Indications (Adults)

Covered when any of the following adult indications apply:

Indications for reimbursable fecal calprotectin testing: Differentiating non-inflammatory gastrointestinal conditions (e.g., irritable bowel syndrome) from inflammatory gastrointestinal disease (e.g., inflammatory bowel disease) OR assessing response to therapy, detecting relapse, or monitoring disease activity in patients with known IBD.adults aged 18 or older

Coverage subject to member benefit limitations and does not apply to Medicare Advantage

Not Reimbursable

Not reimbursable when

Unspecified/other indications: Fecal calprotectin testing for any other situations not described in the reimbursable indications (including individuals under 18 years of age) is not reimbursable due to lack of published evidence of benefit.

Policy states lack of published literature supporting benefit

The coverage criteria in this policy do not apply to individuals less than 18 years of age. Fecal calprotectin testing is reimbursable only when ordered for the specific adult indications listed in this policy (differential diagnosis of non‑inflammatory versus inflammatory GI disease, or monitoring/assessment of IBD). Testing performed for indications other than those stated, or for patients under 18, is not reimbursable.

This medical policy is not applicable to Medicare Advantage members. Providers and members should review the member benefit booklet or contact customer service to determine coverage under Medicare Advantage or other benefit plans.

Fecal calprotectin testing for any situations not described in the reimbursable indications (including uses beyond differentiating IBD from non‑inflammatory conditions or monitoring/assessing IBD therapy or relapse) is considered not reimbursable due to lack of published evidence of clinical benefit.

Coverage and reimbursement are subject to the limits and conditions of the member benefit plan. Providers should verify member benefits prior to testing because coverage may vary by plan, and the policy does not apply to Medicare Advantage.

Coding and Diagnostic Thresholds

Covered CPT CodesCPTCovered

83993

Calprotectin, fecal

Covered CPT CodesCPT

No codes listed

Common fecal calprotectin cutoffs referenced

50 µg/g (manufacturer/common)Most manufacturers quote 50 µg/g as a cutoff for calprotectin kits.

100 µg/gReferenced in diagnostic accuracy analyses and studies as an evaluation threshold for IBD recurrence/diagnosis.

139 µg/gReported as a study-derived predictive cutoff in referenced literature.

150 µg/gOptimal diagnostic accuracy in some meta-analyses and cited by guideline-based clinical decisions (e.g., AGA recommends action thresholds around >150 μg/g).

>160 µg/gCited in studies (ACG) where fecal calprotectin >160 μg/g predicted relapse with high sensitivity and specificity.

Provider Actions, Documentation, and Billing Guidance

Documentation Required

Use with clinical evaluation and appropriate assay

Fecal calprotectin test results are intended to be used in conjunction with the patient’s clinical evaluation and other diagnostic procedures; many assays require performance on a specific analyzer or validated laboratory-developed test. Providers should order and interpret testing only as part of the overall clinical assessment.

Many FDA-cleared assays specify an analyzer (e.g., LIAISON XL) or validated extraction device and must be performed per manufacturer instructions.
Laboratory-developed tests (LDTs) are regulated under CLIA '88 as high-complexity tests and require laboratory validation prior to clinical use.

Documentation Required

Documentation required for reimbursement

Document patient age (≥18 years), the clinical indication (differential diagnosis of IBD vs IBS, assessing response to therapy, monitoring for relapse, or surveillance in known IBD), and the clinical rationale linking the test to patient management. Coverage is limited to the reimbursable indications in this policy; testing for other indications or for individuals under 18 years of age is not reimbursable.

Age must be documented as ≥18 years.

Background and Evidence Summary

Calprotectin is a neutrophil‑derived calcium‑ and zinc‑binding protein released into feces during active intestinal inflammation. Measurement of fecal calprotectin helps distinguish inflammatory bowel disease (IBD) from non‑inflammatory conditions such as irritable bowel syndrome (IBS), and is used to assess response to therapy, detect relapse, and monitor disease activity in patients with known IBD.

Definitions

Fecal calprotectin (definitions)

AbbreviationFecal calprotectin (FC, FCAL).

SpecimenStool (fecal) specimen used to measure calprotectin concentration.

PurposeMarker of intestinal inflammation used to differentiate inflammatory vs non-inflammatory GI disease and to monitor IBD activity.

IBD

DefinitionInflammatory bowel disease, including Crohn's disease (CD) and ulcerative colitis (UC).

Clinical relevanceIBD is an inflammatory GI condition for which fecal calprotectin testing is used for diagnosis and monitoring.

Coverage note

Revision History and Policy Changes

2026-02-06policy_effective_dateLatest

Policy inserted into Routine Test Management Policy and became effective for dates of service on or after February 6, 2026; reimburses fecal calprotectin testing for adults for differentiating IBD from non-inflammatory GI disease and for assessing response to therapy/monitoring relapse.

2025-10-14approval_date

Policy approved by the organization on October 14, 2025 prior to implementation.

2025-11-01

Policy Summary

PayerPremera Bluecross

PolicyFecal calprotectin testing for diagnosis and monitoring of inflammatory bowel disease

Policy CodePolicy G2061

Change TypeNew policy insertion

Effective DateFeb 6, 2026

Next Review Date

Key ActionDocument patient age (≥18), clinical indication, and link testing to management decisions when submitting claims for CPT 83993.

SourceLink

On This Page

Monitoring interval for mucosal healing assessment

Monitoring intervalApproximately 3 to 6 months after treatment initiation for assessment of mucosal healing, per ECCO-ESGAR guidance.

Use with clinical and endoscopic assessmentMucosal healing should be determined by endoscopy or faecal calprotectin in patients who clinically respond to therapy.

Context of response assessmentFaecal calprotectin is recommended alongside clinical parameters and CRP to evaluate treatment response.

Clinical indication must be clearly stated in the medical record.

Link test result to intended clinical management (diagnostic clarification, therapy response, relapse detection, or monitoring of IBD).

Verify member benefit plan for coverage limitations prior to ordering.

Note

Benefit check and plan limitations

Coverage and reimbursement are subject to the limits and conditions of the member benefit plan. Members and providers should consult the member benefit booklet or contact customer service to determine whether there are any applicable benefit limitations. No step therapy requirements are specified in this policy.

Confirm member benefits prior to testing.
No prior authorization or step therapy specified in this policy; follow plan-specific rules if present.

Denial Risk

Denied indications / denial risk

Testing performed for individuals under 18 years of age or for indications other than those listed as reimbursable in this policy may be denied as not reimbursable.

Not reimbursable for patients <18 years.
Not reimbursable for indications outside differential diagnosis between IBD and non-inflammatory GI disease, or monitoring/response/relapse in IBD.

Policy reimburses fecal calprotectin testing for adults (≥18) to differentiate IBD from non-inflammatory conditions and for monitoring.

IBS

DefinitionIrritable bowel syndrome (IBS), a non-inflammatory gastrointestinal disorder.

Diagnostic roleFecal calprotectin and fecal lactoferrin help discriminate IBS from IBD; recommended to rule out IBD in suspected IBS with diarrhea.

Clinical implicationNormal/low fecal calprotectin supports a non-inflammatory diagnosis such as IBS but must be interpreted with clinical context.

Faecal calprotectin (FC)

RoleA stool marker of colonic inflammation with good validity and responsiveness for monitoring IBD; rises with relapse and falls with successful treatment.

PerformanceConsidered to have good validity and responsiveness; used as a noninvasive surrogate for endoscopic activity in monitoring.

LimitationsRisk of false-positive results (e.g., infectious gastroenteritis); values between 50–150 µg/g may require repeat testing after 2–3 weeks.

Fecal lactoferrin (FL)

DefinitionFecal lactoferrin (FL) — a fecal-derived marker of intestinal inflammation.

Comparison to FCLike fecal calprotectin, fecal lactoferrin can help discriminate IBD from IBS and may be superior to some serologic tests for this purpose.

UseUsed as an adjunctive noninvasive test to identify intestinal inflammation alongside calprotectin and CRP.

Document history notes a new policy entry (11/01/25) describing approval and planned effective date, with 90-day provider notification and placement in Routine Test Management Policy section.